Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2014, Article ID 489686, 3 pages
http://dx.doi.org/10.1155/2014/489686
Case Report

Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy

1Department of Internal Medicine, Florida Hospital, Orlando, FL 32804, USA
2Cancer Institute of Florida, Florida Hospital, 2501 North Orange Avenue, Suite 689, Orlando, FL 32804, USA

Received 24 June 2014; Accepted 6 August 2014; Published 18 August 2014

Academic Editor: Fumitaka Koga

Copyright © 2014 Yasmin M. Abaza and Carlos Alemany. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Wang, P. Bai, H. Su, G. Luo, Z. Zhong, and X. Zhao, “Management of primary adenocarcinoma of the female urethra: report of two cases and review of the literature,” Oncology Letters, vol. 4, no. 5, pp. 951–954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Swartz, M. P. Porter, D. W. Lin, and N. S. Weiss, “Incidence of primary urethral carcinoma in the United States,” Urology, vol. 68, no. 6, pp. 1164–1168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. D. Grivas, M. Davenport, J. E. Montie, L. P. Kunju, F. Feng, and A. Z. Weizer, “Urethral Cancer,” Hematology/Oncology Clinics of North America, vol. 26, no. 6, pp. 1291–1314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. W. J. Gradishar, D. Krasnojon, S. Cheporov et al., “Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival,” Clinical Breast Cancer, vol. 12, no. 5, pp. 313–321, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. D. Von Hoff, T. Ervin, F. P. Arena et al., “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine,” The New England Journal of Medicine, vol. 369, no. 18, pp. 1691–1703, 2013. View at Google Scholar
  6. Y.-J. Ko, C. M. Canil, S. D. Mukherjee et al., “Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study,” The Lancet Oncology, vol. 14, no. 8, pp. 769–776, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. L. Blum, M. A. Savin, G. Edelman et al., “Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes,” Clinical Breast Cancer, vol. 7, no. 11, pp. 850–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. D. Seidman, D. Berry, C. Cirrincione et al., “Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1642–1649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Itoh, K. Mitsuzuka, S. Kimura et al., “cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma,” International Journal of Urology, vol. 21, no. 4, pp. 422–424, 2014. View at Publisher · View at Google Scholar
  10. H. von der Maase, L. Sengelov, J. T. Roberts et al., “Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4602–4608, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Dayyani, C. A. Pettaway, A. M. Kamat, M. F. Munsell, K. Sircar, and L. C. Pagliaro, “Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists,” Urologic Oncology, vol. 31, no. 7, pp. 1171–1177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Desai, V. Trieu, B. Damascelli, and P. Soon-Shiong, “SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients,” Translational Oncology, vol. 2, no. 2, pp. 59–64, 2009. View at Publisher · View at Google Scholar · View at Scopus